<--- Back to Details
First PageDocument Content
Tuberculosis / Bacillus Calmette-Guérin / Vaccines / Bladder cancer / Transitional cell carcinoma / Immunotherapy / End point of clinical trials / Cancer cell / BCG as a treatment for bladder cancer / Medicine / Oncology / Cancer treatments
Tuberculosis
Bacillus Calmette-Guérin
Vaccines
Bladder cancer
Transitional cell carcinoma
Immunotherapy
End point of clinical trials
Cancer cell
BCG as a treatment for bladder cancer
Medicine
Oncology
Cancer treatments

An upper limit for macromolecular crowding effects

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Download Document from Source Website

File Size: 851,86 KB

Share Document on Facebook

Similar Documents

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

DocID: 1vdls - View Document

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

DocID: 1uTyz - View Document

April 18, 2018 Torii Pharmaceutical Co., Ltd. Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Poll

DocID: 1uM8x - View Document

第42回 日本免疫学会学術集会 クリニカルセミナー 2 Sublingual immunotherapy for Japanese cedar pollinosis

DocID: 1untY - View Document

President of ORPHEUS Robert Adam Harris Professor in Immunotherapy in Neuroinflammation Karolinska Institutet Personal details:

DocID: 1u6T9 - View Document